Assignee
INCYTE HOLDINGS CORP
US·12 granted patents·2 pending applications·69 citations·filing 2015–2025
Top patents by PatentIndex Score
14 records- 0198US11213528B2Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrileINCYTE HOLDINGS CORP·Filed 2020·Granted Jan 4, 2022·5 cites·16 claims
- 0297US10610530B2Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrileINCYTE HOLDINGS CORP·Filed 2018·Granted Apr 7, 2020·8 cites·28 claims
- 0396US10975085B2Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula IIIINCYTE HOLDINGS CORP·Filed 2019·Granted Apr 13, 2021·5 cites·8 claims
- 0496US10364248B2Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidineINCYTE HOLDINGS CORP·Filed 2018·Granted Jul 30, 2019·5 cites·13 claims
- 0596US9988387B2Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitorsINCYTE HOLDINGS CORP·Filed 2015·Granted Jun 5, 2018·9 cites·12 claims
- 0695US10016429B2Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrileINCYTE HOLDINGS CORP·Filed 2016·Granted Jul 10, 2018·10 cites·12 claims
- 0795US9944645B2Imidazotriazines and imidazopyrimidines as kinase inhibitorsINCYTE HOLDINGS CORP·Filed 2016·Granted Apr 17, 2018·15 cites·15 claims
- 0895US9908888B2Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidinesINCYTE HOLDINGS CORP·Filed 2016·Granted Mar 6, 2018·6 cites·8 claims
- 0994US10472367B2Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitorsINCYTE HOLDINGS CORP·Filed 2018·Granted Nov 12, 2019·5 cites·18 claims
- 1090US12226419B2Topical formulation for a JAK inhibitorINCYTE HOLDINGS CORP·Filed 2024·Granted Feb 18, 2025·0 cites·20 claims
- 1185US10919901B2Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitorsINCYTE HOLDINGS CORP·Filed 2019·Granted Feb 16, 2021·1 cites·12 claims
- 1280US2022288078A1Salts of the Janus Kinase Inhibitor (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-YL)-1h-Pyrazol-1-Yl)-3- CyclopentylpropanenitrileINCYTE HOLDINGS CORP·Filed 2021·Application pending·0 cites
- 1378US12247030B2Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidineINCYTE HOLDINGS CORP·Filed 2021·Granted Mar 11, 2025·0 cites·10 claims
- 1478US2025340559A1Processes for preparing jak inhibitors and related intermediate compoundsINCYTE HOLDINGS CORP·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when INCYTE HOLDINGS CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →